Group 1 - The core viewpoint of the article highlights that Valiant Bio-B (09887) has seen a significant increase in stock price, rising over 6% following the announcement of its inclusion in the Hang Seng Composite Index [1] - As of the report, Valiant Bio-B's stock price is at 65.1 HKD with a trading volume of 18.6588 million HKD [1] - The inclusion in the Hang Seng Composite Index will take effect after the market closes on March 6, 2026, and will be effective from March 9, 2026, which may lead to adjustments in the Hong Kong Stock Connect investment scope [1] Group 2 - Valiant Bio-B has announced the successful administration of its drug, VILISEN™ (PD-L1/4-1BB bispecific antibody Opalizumab, LBL-024), to the first patient in a Phase Ib/II clinical trial for treating recurrent or metastatic triple-negative breast cancer [1] - The open-label, multicenter Phase Ib/II clinical study is led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital and is being conducted across multiple hospitals nationwide [1] - The trial aims to evaluate the efficacy and safety of Opalizumab either as a monotherapy or in combination with albumin-bound paclitaxel for patients with recurrent or metastatic triple-negative breast cancer [1]
港股异动 | 维立志博-B(09887)涨超6% 公司获纳入恒生综合指数有望入通